GET DAILY SIGNALSMetagenomi Therapeutics (MGX): What to Watch Ahead of Q3 2026 Earnings
Key Takeaways
- Metagenomi Therapeutics (NASDAQ: MGX) is expected to report its third-quarter 2026 results in mid-November, following its Q2 report released on August 10, 2026.
- Wall Street consensus points to a net loss of roughly $0.62 to $0.64 per share, with collaboration-driven revenue expected to fall sharply from the $8.66 million recorded a year ago.
- The clinical-stage genome editing company's most important updates are pipeline-focused: lead program MGX-001 for hemophilia A is on track for an investigational new drug (IND) filing in Q4 2026.
- As of June 30, 2026, Metagenomi held approximately $120.7 million in cash, cash equivalents, and marketable securities, with a runway anticipated into the fourth quarter of 2027.
- The prior quarter missed expectations, posting a GAAP loss of $0.73 per share versus a roughly $0.55 consensus, largely due to a collaboration revenue reversal.
- You can track the latest developments on the Major News page, review Today's Price Move, check analyst Price Targets, and explore the stock's Forecast.
- To discover AI-powered trade ideas and market opportunities, explore Tickeron's Trending AI Robots.
Why the Earnings Context Matters for Investors
Metagenomi Therapeutics (MGX) is an in vivo genome editing company developing curative genetic medicines. As a pre-commercial biotech, its quarterly income statement tells investors less than its clinical milestones and balance-sheet durability. Collaboration revenue has been shrinking as partnered programs wind down, which explains the steep expected year-over-year decline. What investors are really watching is whether MGX-001, a potential one-time therapy for hemophilia A, stays on schedule for an IND submission in the fourth quarter of 2026 and a global clinical trial in 2027. With the stock trading well below its 52-week high, this report offers a key checkpoint on both execution and cash runway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Projecting for the Quarter
Analysts expect Metagenomi to report a third-quarter 2026 net loss of approximately $0.62 to $0.64 per share (EPS, or earnings per share), versus a loss of $0.55 per share in the same period a year earlier. Consensus revenue estimates sit in the low single-digit millions — roughly $2.1 million to $2.6 million — a decline of more than 70% from the $8.66 million reported in Q3 2025 as collaboration revenue diminishes. Given the company's pre-revenue stage, the headline loss figure is secondary; operating expenses, R&D (research and development) spending, and the reported cash balance are the metrics analysts will scrutinize. In Q2 2026, Metagenomi missed consensus with a GAAP (Generally Accepted Accounting Principles) loss of $0.73 per share on a revenue reversal, so investors will be alert for any similar collaboration-driven volatility.
How the Market Is Approaching the Report
Sentiment heading into this report is cautious. MGX shares have declined sharply over the trailing twelve months and currently sit near the lower end of their 52-week range, reflecting both broad pressure on small-cap biotech and disappointment following the Q2 2026 miss. With a market capitalization of only a few tens of millions of dollars and a limited public float, the stock remains vulnerable to outsized moves on any pipeline or cash news. The key risk factors investors are weighing include potential delays to the MGX-001 IND timeline, higher-than-expected R&D burn, and continued erosion of collaboration revenue. Conversely, any confirmation that the hemophilia A program remains on track could act as a stabilizing catalyst.
Key Factors to Monitor Going Forward
Looking ahead, the single most important near-term catalyst is the planned IND submission for MGX-001 in the fourth quarter of 2026. Management has repeatedly reaffirmed this timeline, and any shift in language could meaningfully reshape sentiment.
Investors should also monitor the company's cash position and runway. With roughly $120.7 million in cash and marketable securities as of mid-2026 and a runway anticipated through the fourth quarter of 2027, the company has flexibility — but rising R&D costs as it prepares to enter the clinic will be a key line item to track.
Finally, watch for updates on partnership and collaboration revenue, which has been a source of quarter-to-quarter volatility. Because Metagenomi remains pre-revenue from product sales, its financial story will continue to hinge on execution against clinical milestones and disciplined capital management rather than top-line growth.
Using AI Tools in Biotech Research
When evaluating names like this, I often rely on Tickeron's AI Screener to quickly filter for relevant technical patterns, fundamentals, and industry peers. It helps surface ideas and compare metrics without manual effort, which is especially useful for volatile, catalyst-driven stocks. The tool supports customizable scans across thousands of securities and can highlight potential opportunities based on user-defined criteria. Explore the AI Screener to build a watchlist tailored to your criteria.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MGX's RSI Indicator slumps into oversold zone
The RSI Oscillator for MGX moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 21 of 30 cases where MGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.
Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for MGX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement